Michael Young, MD
Allergy & Immunology · South Weymouth, MANPI 1609864560
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,211 of the $10,583 with a category attached, or 77.6%. It is spread thinly across 40 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations.
Across 380 payments — averaging $27.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aimmune Therapeutics, Inc.$2K
- AstraZeneca$1K
- GSK$907
- Takeda Pharmaceuticals U.S.A., Inc.$632
- CSL Behring$505
- Regeneron Healthcare Solutions, Inc.$504
- plus $4K from 34 others
What the payments were for
- Consulting fees$2,23821%
- Food & beverage$8,21178%
- Education$1331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aimmune Therapeutics, Inc. | 9 | $2,378 |
| AstraZeneca | 57 | $1,468 |
| GSK | 48 | $907 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $632 |
| CSL Behring | 23 | $505 |
| Regeneron Healthcare Solutions, Inc. | 24 | $504 |
| Grifols USA, LLC | 26 | $423 |
| Amgen | 18 | $381 |
| Genentech USA, Inc. | 22 | $373 |
| Novartis | 16 | $349 |
| AbbVie | 10 | $298 |
| Biocryst US Sales Co., LLC | 9 | $263 |
| Sanofi | 10 | $229 |
| Pharming Healthcare, Inc. | 9 | $217 |
| Pfizer | 10 | $200 |
| Teva Pharmaceuticals USA, Inc. | 6 | $168 |
| Kaleo, Inc. | 7 | $138 |
| Boehringer Ingelheim | 6 | $125 |
| Blueprint Medicines Corporation | 6 | $116 |
| Glaukos Corporation | 1 | $98 |
| Ionis Pharmaceuticals, Inc. | 2 | $75 |
| Covis Pharma GmbH | 3 | $73 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $69 |
| Alk-abello, Inc | 3 | $60 |
| Greer Laboratories, Inc. | 2 | $54 |
| Verona Pharma, Inc. | 2 | $49 |
| Incyte Corporation | 2 | $48 |
| GC Biopharma USA, Inc. | 2 | $48 |
| Octapharma USA, Inc. | 2 | $45 |
| Shire North American Group Inc | 2 | $43 |
| Merck | 2 | $37 |
| Dermavant Sciences, Inc. | 1 | $29 |
| Hikma Pharmaceuticals USA | 2 | $27 |
| LEO Pharma Inc. | 1 | $26 |
| Phadia US Inc. | 1 | $24 |
| Cycle Pharmaceuticals Inc | 1 | $24 |
| ADMA Biomanufacturing LLC | 2 | $23 |
| Bio Products Laboratory USA, Inc. | 1 | $20 |
| Invivyd Inc | 1 | $18 |
| USWM, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,583 in reported general payments places this provider in the 65th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 39 | $174,595 |
| Dupixent SyringeDupilumab | 34 | $152,981 |
| Dupixent PenDupilumab | 26 | $95,839 |
| XolairOmalizumab | 20 | $54,075 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $20,723 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $20,686 |
| Fluticasone Propionate HfaFluticasone Propionate | 31 | $19,860 |
| Spiriva RespimatTiotropium Bromide | 27 | $19,020 |
| DuleraMometasone/Formoterol | 33 | $17,612 |
| Arnuity ElliptaFluticasone Furoate | 56 | $16,450 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $13,316 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $11,438 |
| Wixela InhubFluticasone Propion/Salmeterol | 46 | $10,789 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $9,878 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $9,378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $632 | $174,59539 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta, Incruse Ellipta | $907 | $67,737122 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,468 | $22,69443 claims |
| Boehringer IngelheimSpiriva Respimat | $125 | $19,02027 claims |
| MerckDulera | $37 | $17,61233 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $168 | $5,44114 claims |
| Hikma Pharmaceuticals USAEpinephrine | $27 | $4,99124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 114 allergy & immunology providers in Massachusetts.
Other allergy & immunology in South Weymouth
- Martin BroffSouth Weymouth$3K
- Wanda PhipatanakulBoston$679K
- Jonathan BayukNorthampton$420K
- Kathleen BuchheitBoston$224K
- Francisco BonillaLeominster$188K
- Aleena BanerjiBoston$133K
- Margo StevensonSturbridge$98K
- Jeffrey GelfandBoston$84K
- Paul MaglioneBoston$66K
- Maria CastellsGardner$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.